Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Ethical and Policy Challenges to Clinical Application of Advanced Genetic Screening Technology Edward RB McCabe, MD, PhD Physician-in-Chief, Mattel Children’s Hospital at UCLA Professor, Departments of Pediatrics and Human Genetics Director, UCLA Center for Society, the Individual and Genetics http://www.arc2.ucla.edu/csig/ Genomic Medicine • Anticipatory, not reactive • Predictive and preventive • Knowledge from genomics and derivative disciplines • Screening of individuals and populations • New analytical technologies and bioinformatic approaches Genomic Medicine: Challenges • Requires change in culture – Practitioners • Preventive medicine approach • Less independence – Population • Lifestyle • Participation in large clinical trials Genomic Medicine: Challenges • Requires change in medical data analysis – Driven by lab data not knowledge (at least initially) of pathogenesis – Huge amount of information – Pattern recognition Genomic Medicine: Challenges • Requires change in diagnostic approach – Trust in unseen algorithms – Evaluation of matrices and dynamic complex systems, not linear pathways – Less hypothesis-driven and increasing reliance on protocols Genomic Medicine: Consequences • Balance between art and science will shift toward the science, at least in the predictive screening and diagnostic areas • Cannot lose the art of medicine, because that will be essential for successful implementation of preventive and therapeutic measures Genomic Medicine: Consequences • Reduction of the burden of chronic illness • Decrease in the prevalence of common complex diseases • Increase in health disparities between those with and without access to genomic medicine • Technological spin-offs in other areas of medicine including infectious diseases How Have We Gotten Here and What Have We Already Learned? Watson and Crick, May 1953 From Olby, The Path to the Double Helix, 1974 Human Genome Project • Initiated 1990 • Completion originally planned for 2005 • Finished sequence anticipated Spring, 2003, to commemorate the 50th Anniversary of Watson and Crick publication (Nature 171: 737-738, April 25, 1953) Human Genome Project • Results – Complete sequencing of the Human Genome – New branch of science and medicine – Genomics What Is a Genome? • Genome: All of the DNA for an organism • Human Genome – Nucleus: 3.2 billion base pairs packaged into chromosomes – Mitochondrion: 16,600 base pairs packaged in one circular chromosome Genomics: Derivative Disciplines • Transcriptomics – Transcript is an RNA copy of a gene – Transcriptome is all RNA gene copies in a cell, tissue or individual • Proteomics – Proteome is all proteins in a cell, tissue or individual Genomics: Derivative Disciplines • Metabolomics – Metabolome is all of the small molecule components of a cell, tissue or individual that are produced by the proteins of the proteome Thorough Understanding of Genomics Will generate the complete parts lists and the parts’ assembly directions for fully functioning organisms What have we already learned from genetics and genomics? We are not the center of the biosphere! Galileo Galilei. Dialogo… Tolemaico, e Copernicano… Florence, 1632 Aristotle, Ptolemy, and Copernicus Homeobox Genes There is No Biological Basis for the Concept of Race! • There is more genetic variation within ethno-cultural groups than there is between them • Therefore, even the terminology “race” is erroneous conceptually • Corollary: – There is no biological basis for racism Even Our Ethno-Cultural Identity May Be Challenged by Genetics/Genomics • For many of us, our knowledge of our heritage is quite limited – Three-generation pedigrees – Surnames – Family lore • Therefore, we may be open for surprises if genetic/genomic technologies ever allow accurate evaluation of biological inheritance Even the Concept of Two Sexes Lacks Biological Rigor! • The dichotomous (male/female) concept of gender denies modern genetic and social observations • An individual’s sex may be defined in various ways, and they may not all be synchronous for a specific individual Modern Concepts of Sex/Gender • • • • • • Sex of rearing Genital sex Chromosomal sex Genetic sex Legal sex Gender identity Modern Concepts of Sex/Gender • Even biological concepts of sex/gender indicate a continuum and not a dichotomy • There may be a conflict in sexual assignments even when using biological criteria, e.g.: – 46,XY female: SRY– 46,XX male: SRY+ – 46,XY(SRY+) female: DAX1 duplication What have we already learned from genetics and genomics? • Fundamental and well-accepted concepts are not supported by the lessons from modern genetics and genomics • If we must re-think our position in the biosphere, and our ethno-cultural and sexual identities, then how else will genomics and genetics influence our concepts of self? Influence of Genetics/Genomics on Concepts of Disease • All disease has one or more genetic components • Therefore, we are all at risk for genetic diseases • If we accept these statements, then there is no basis for genetic discrimination, since we are all in the same risk pool • But the insurance industry is based on the ability to discriminate and assign risk Influence of Genetics/Genomics on Concepts of Disease • At this point in the evolution of our knowledge, we have the information to permit us to identify predisposition to certain relatively rare genetic diseases, e.g., CF, Huntington disease, etc. • The burden of genetic disease, however, is among all of us with predisposition to common, complex genetic disease, e.g., cancer, cardiovascular disease, diabetes mellitus, etc. Manhattan Project of Biology • “We have just come through the Manhattan project of biology. Let’s get it right this time!” Al Carnesale, Chancellor, UCLA – Ethical, Legal and Social Issues (ELSI) Program, NIH – UCLA Center for Society, the Individual and Genetics – US DHHS Secretary’s Advisory Committee on Genetic Testing (SACGT) and Secretary’s Advisory Committee on Genetics, Health and Society (SACGHS) Small Businesses and Health Insurance A patient who works for a small selfinsured company has a positive family history for emphysema on both her mother’s and her father’s sides. Her physician recommends that she have a number of tests performed, including one for 1-antitrypsin (1AT). Small Businesses and Health Insurance When the 1AT test is reported to be abnormal, he tells her that this may explain the emphysema in her family and places her at very high risk for this lung disease. Her physician reports the results of his evaluation to her insurance company as required. Several days later she is called into the office of her employer and fired. Small Businesses and Health Insurance • Actual case: Patient had symptoms at time of testing • Commissioner Paul Miller, EEOC, argued this case under ADA • Settled in favor of employee • Remains to be determined whether an abnormal test result in the absence of physical signs and symptoms would be covered by ADA Invasion of Genetic Privacy Workers for Burlington Northern Railroad gave blood sample as part of company physical examination. Portion of sample sent to a private laboratory for PMP22 (Peripheral Myelin Protein-22) deletion testing. This deletion is associated with HNPP (Hereditary Neuropathy with liability to Pressure Palsies), a slowly progressive neuropathy that may present with carpal tunnel syndrome. Invasion of Genetic Privacy Workers did not know genetic testing for HNPP was being done and did not provide consent for testing. Union brought suit against BNRR and testing was stopped. Invasion of Genetic Privacy • Informed consent has been recommended for all genetic testing • There needs to be a firm evidence-base for any genetic test to move into the clinical arena • Therefore, “labeling” of genetic tests is essential for health professionals and their patients Direct-to-Consumer Marketing of Genetic Testing A 25 y.o. with a very strong positive family history of breast cancer (mother, maternal aunt, maternal great aunt, all with presentation before age 40) sees a DTC ad for BRCA1 and BRCA2 testing. Testing was not performed on her mother, who died in 1987. This woman is one of three sisters. Direct-to-Consumer Marketing of Genetic Testing The cost of testing these two genes is $2,800 without a known mutation. She elects to pay this out-of-pocket to avoid informing her primary care physician and insurance company of the testing. Direct-to-Consumer Marketing of Genetic Testing • If a mutation is identified: – Consideration of interventions – Discussions with sisters and other relatives – Impact on health insurance • If no mutation is identified: – Influence on medical decision-making – Discussions with sisters and other relatives – Impact on health insurance Direct-to-Consumer Marketing of Genetic Testing Zitner, LA Times, Sunday, August 11, 2002 • DTC genetic testing for: – Drug metabolizing enzymes – Vitamin mix selection – Personalized health and nutritional advice (e.g., MTHFR) – Hereditary hemochromatosis – Cystic fibrosis – Factor V Leiden Direct-to-Consumer Marketing of Genetic Testing • Home genetic testing – Equipment under development by several companies – Determining market at this time • What will be role of health care provider in test interpretation? GeneFluidics’ Solution Biofluidic chip Biological agent 1.2 inches 4 inches Genetic material Proteins, Ions DNA micro sensor array The $1,000 Genome • Acquisition – Error rate • Interpretation – Lack of evidence-base • Privacy – Information storage • Discrimination – Abnormality vs. normal variation Storefront Genome UCLA January 26, 2003 9 am – 5 pm Sunset Village Conference Center http://www.arc2.ucla.edu/csig/ Changing Clinics A family has a 5 yo who has a rare genetic disease and has been followed in the same clinic since she was diagnosed in the neonatal period. They move to a new state and are told that the care will be altered significantly because this new clinic has a different approach to management. Reasons for Differing Clinical Practices in Medical Genetics • Practice of medicine – “An art not a science” – Practitioner-based – Not subject to regulation • Case series for most rare genetic diseases – Quite small – Not organized for iterative improvement Collaborative, Multi-Institutional, Protocol-Driven Clinical Studies • An approach to make progress toward a sound evidence-base when individual patients are rare • Example from genetic disease – Double blinded study of the value of penicillin prophylaxis for Sickle Cell Disease (Gaston et al, NEJM 1986) Collaborative, Multi-Institutional, Protocol-Driven Clinical Studies • Children’s Oncology Group: Most successful example – At least 85% of children with cancer enrolled in research protocols – Permits an iterative approach to interventional changes – Credited with success of pediatric cancer outcomes Multitude of Genotypes Even for “Common Disease” Phenotypes • Since complexity is the rule for “simple” Mendelian traits as well as “common” disorders • Therefore, the rare and common disorders will both be composed of individuals with rare composite genotypes • Consequence: We can develop similar approaches for acquisition of an evidence-base across genetic diseases Collaborative, Multi-Institutional, Protocol-Driven Clinical Studies • The highly individualistic approach that provides the medical geneticist with management autonomy delays progress unnecessarily • An organized national approach will require – Buy-in by the medical genetics community – Resources to support protocols Participation of Normal Individuals in Large Studies You are asked to enroll in a genetic predisposition study. It will include those who agree to participate from at least 500,000 individuals who have been selected randomly. Participants will answer a detailed questionnaire and will have mutation analysis performed for the gene of interest. Participation of Normal Individuals in Large Studies Participants will be followed throughout their lives to determine whether or not they develop this or any related diseases. Large Clinical Studies • Population – Representative? – Biased? • Data release – Participants? – Health care providers? – Insurance providers? Large Clinical Studies • Monetary – Source of support for trial? – Payment for medical care? • Uniformity – Diagnostic criteria? – Practitioner training? – Ongoing data collection? Large Clinical Studies • Hemochromatosis study • Cystic fibrosis newborn screening studies – Colorado – Wisconsin • California tandem mass spectrometry pilot Genetic Census: UK Biobank Kinkead, NY Times: Dec 31, 2002 • Planning initiated 1999 • Will begin in 2003 • Goal over next 10-20 yrs – To investigate role of genes and environment in common diseases – Planned in anticipation of time when individuals will be able to sequence their genomes and will want to know the implications for their disease risk Genetic Census: UK Biobank Kinkead, NY Times: Dec 31, 2002 • Project cost – $120M – Financed by UK government, the Wellcome Trust, and Medical Research Council Genetic Census: UK Biobank Kinkead, NY Times: Dec 31, 2002 • 1.2M healthy individuals ages 45-69 yrs will contribute blood specimens – DNA will be prepared and frozen • 500,000 individuals will be chosen to be followed for 10 yrs through NHS records • At intake – 10 page comprehensive questionnaire – 10 day diet diary – Brief health exam Genetic Census: UK Biobank Kinkead, NY Times: Dec 31, 2002 • Data separate from NHS record – Anonymous but not completely – Updates possible from physicians and new questionnaires • Anticipate by 2014 – 40,175 will have cancer, diabetes, heart disease or stroke – 6,200 will have dementia, hip fractures, Parkinson disease or rheumatoid arthritis Genetic Census: UK Biobank Kinkead, NY Times: Dec 31, 2002 • Single nucleotide polymorphisms (SNPs) will be analyzed • Will compare SNPs with epidemiologic information • Milburn, UK Health Secretary: – “…flagship project on molecular epidemiology for the new century.” Genetic Census: UK Biobank Kinkead, NY Times: Dec 31, 2002 • Has been slow to start because of ethical concerns • Critics: – Individuals will be exploited – Privacy will be invaded – Access by courts and pharmaceutical companies – Studies to be permitted not fully defined Other Genetic Database Projects Kinkead, NY Times: Dec 31, 2002 • 1970’s – Nurse’s Health 121,701 • 1980’s – Sweden 80,000 – Framingham, MA >4,000 – Am Cancer Society 110,000 Other Genetic Database Projects Kinkead, NY Times: Dec 31, 2002 • 1992 – Epic (10 European countries) 520,000 • 2002 – Marshfield, WI (Personalized Medicine Project) 42,000 • 2003-2005 – 7 projects planned with 50,000 to 1M each Cloning Humans On December 27, 2002, at a press conference at a Holiday Inn in Hollywood, FL, the birth of a healthy 7 lb baby girl on December 26, 2002, was announced. Nicknamed Eve, the baby was born at an undisclosed location outside of the USA to a 31 yo American woman from whom Eve was cloned. Cloning Humans The announcement of the birth of the first cloned human was made by Dr. Brigitte Boisselier, a chemist and the head of a private company, Clonaid. She said that four other women were pregnant with Clonaid-created clones, and 20 more women were scheduled for implantation of cloned fetuses in January, 2003. Cloning Humans Clonaid was founded by Claude Vorilhon, a former race car driver. He also formed the Raëlians, a worldwide “atheistic religion” of 55,000 followers. They believe that memories and consciousness transfer from an individual to their clone, and therefore cloning is the path to eternal life. Cloning Humans • Two additional groups have claimed that they they are close to creating human clones • No other primate has been cloned • Health risks well documented for other mammals – Clones – Mothers Cloning Humans • IOM committee report – Reproductive cloning should be banned with criminal penalties because of risks – Therapeutic cloning should be encouraged – The issue of cloning and the data from other mammals should be re-evaluated in 3-5 years Summary • Genomic Medicine – Offers great promise – Also significant challenges • Will require significant changes by – Practitioners – Public Summary • Genomic medicine will foster significant tension between the art and science of medicine • Incredibly complex technology will require Medical Genetics expertise – Analogy with Radiology and imaging technologies: Used by all areas of medicine but need specialists knowledgeable in the technological fine points